HCW Biologics Advances HCW9302 in Alopecia Areata
MIRAMAR, Fla., August 14, 2026 HCW Biologics Inc. (NASDAQ: HCWB) reported second-quarter 2026 business and clinical development updates, highlighting...
alopecia areata
Advertisement
argenx SE Expands Immunology Pipeline with Forte Biosciences Deal
Amsterdam, the Netherlands and Dallas, Texas – July 27, 2026 argenx has entered into a definitive agreement to acquire...
Q32 Bio Reports Positive Phase 2a Alopecia Trial Results
WALTHAM, Mass., July 13, 2026 Q32 Bio has announced positive 36-week topline results from Part B of the Phase...
Roche Enspryng Gains FDA Priority Review for TED Treatment
BASEL, Switzerland, June 30, 2026 Roche has announced that the U.S. Food and Drug Administration (FDA) has granted Priority...
AbbVie RINVOQ® Moves Closer to EU Approval for Alopecia Areata
NORTH CHICAGO, Ill., June 29, 2026 AbbVie has announced that the European Medicines Agency’s Committee for Medicinal Products for...
Advertisements
Astellas and Pfizer Gain FDA Priority Review for PADCEV Combo
TOKYO, Japan and NEW YORK, U.S., April 20, 2026 Astellas Pharma Inc. and Pfizer Inc. have announced that the...
Nektar Rezpegaldesleukin Shows 52-Week Alopecia Results
SAN FRANCISCO, April 20, 2026 Nektar Therapeutics has reported compelling 52-week topline results from the Phase 2b REZOLVE-AA trial,...
Rezpegaldesleukin Shows Strong Phase 2b Results in AD
San Francisco, USA | March 28, 2026 Phase 2b Data Demonstrates Strong Clinical Efficacy Nektar Therapeutics has announced compelling...
Nektar Therapeutics Reports Phase 2b Rezpegaldesleukin Data
San Francisco, California, USA | March 20, 2026 Nektar Therapeutics has announced that Phase 2b clinical data for rezpegaldesleukin,...
Legacy Advances Cinainu into Phase 3 Alopecia Areata Trial
LAUSANNE, Switzerland | January 6, 2026 — Legacy Healthcare announced that it will advance its topical botanical drug candidate,...
Advertisement
